InsiderSignal.AI

InsiderSignal.ai

VYGR - Voyager Therapeutics, Inc.

Insider Sale by Sandrock Alfred (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Sandrock Alfred, serving as Pres, CEO at Voyager Therapeutics, Inc. (VYGR), sold 11,511 shares at $3.87 per share, for a total transaction value of $44,548.00. Following this transaction, Sandrock Alfred now holds 472,549 shares of VYGR.

This sale represents a 2.00% decrease in Sandrock Alfred's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, April 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 1 day after the trade was made.

Voyager Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Sandrock Alfred

Sandrock Alfred

Pres, CEO

Alfred W. Sandrock, Jr., M.D., Ph.D. is the President and Chief Executive Officer of Voyager Therapeutics, a position he has held since 2022, along with membership on the company's board of directors[[1]](https://www.voyagertherapeutics.com/about-leadership/). He brings extensive expertise in biopharmaceutical drug development, having spent 23 years at Biogen where he advanced through positions of increasing responsibility, culminating in his role as Executive Vice President of Research and Development[[1]](https://www.voyagertherapeutics.com/about-leadership/). During his tenure at Biogen, Sandrock served as Chief Medical Officer and held a seat on the Executive Committee, overseeing the discovery, development, and regulatory approval of numerous medicines including SPINRAZA®, TECFIDERA®, TYSABRI®, PLEGRIDY®, and ADUHELM™[[1]](https://www.voyagertherapeutics.com/about-leadership/). Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University[[1]](https://www.voyagertherapeutics.com/about-leadership/). He completed clinical training including an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital[[1]](https://www.voyagertherapeutics.com/about-leadership/). In addition to his CEO role at Voyager Therapeutics, Sandrock serves on the boards of Verge Genomics, Inc., Transition Bio, Inc., and Neurimmune, Inc.[[1]](https://www.voyagertherapeutics.com/about-leadership/)

View full insider profile →

Trade Price

$3.87

Quantity

11,511

Total Value

$44,548.00

Shares Owned

472,549

Trade Date

Thursday, April 2, 2026

2 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Voyager Therapeutics, Inc.

Company Overview

No company information available
View news mentioning VYGR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5335754

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime